Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
QLI Stock Summary
In the News
Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2021
Jiuquan, China, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021.
Qilian International Holding Group Limited Signs Agreement with District Government, Settling the Project in Local High-tech Zone
Jiuquan, China, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company, through its PRC subsidiary Chengdu Qilianshan Biotechnology Co., Ltd. (“Chengdu QLS”), entered into an agreement (the “Agreement”) with Chongqing Tongnan District Government (“CTDG”). Pursuant to the Agreement, the Company's new pig by-product processing facility (the “Project”) will be located in Tongnan High-tech Zone. CTDG agrees to provide the Company with preferential policies and support funds.
Qilian International Holding Group Limited Enters into Investment Agreement for Pig By-product Processing Project in Chongqing
Jiuquan, China, July 09, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company, through its PRC subsidiary Chengdu Qilianshan Biotechnology Co., Ltd., has entered into an investment agreement (the "Agreement") with Chongqing Jin Tong Industrial Construction Investment Co. Ltd. (“CJT”) on July 5, 2021, for the construction of a pig by-product processing facility (the “Project”) in Chongqing.
QLI Stock Price Increased Over 10% Pre-Market: Why It Happened
The stock price of Qilian International Holding Group Ltd (NASDAQ: QLI) increased by over 10% pre-market. This is why it happened.
Qilian International Holding Group Limited Reports Fiscal Year 2020 Financial Results
Jiuquan, China, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced its financial results for the fiscal year ended September 30, 2020.
Qilian International Holding Group Limited to Triple Organic Fertilizer Production Capacity by March 2021
Jiuquan, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced that the Company will complete the first phase expansion of its new organic fertilizer production facility and put it into production in Jiuquan City, Gansu Province by March 2021. The Company expects to triple its organic fertilizer production capacity upon completion of its first phase expansion.
U.S. IPO Week Ahead: Bumble's Billion-Dollar Deal Leads A Buzzy 11 IPO Week
U.S. IPO Week Ahead: Bumble's Billion-Dollar Deal Leads A Buzzy 11 IPO Week
Qilian International Holding Group Limited Announces Closing of Initial Public Offering
Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.
QLI Financial details
QLI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.32 | 1.43 | 1.68 | 1.81 | 1.3 | |
Net income per share | 0.15 | 0.14 | 0.09 | 0.03 | -0.22 | |
Operating cash flow per share | -0.02 | 0.15 | 0.01 | 0.35 | 0.01 | |
Free cash flow per share | -0.03 | 0.13 | -0.09 | 0.26 | -0.1 | |
Cash per share | 0.13 | 0.34 | 0.31 | 0.4 | 0.63 | |
Book value per share | 0.57 | 0.75 | 1.61 | 1.48 | 1.2 | |
Tangible book value per share | 0.59 | 0.77 | 1.61 | 1.49 | 1.15 | |
Share holders equity per share | 0.57 | 0.75 | 1.61 | 1.48 | 1.2 | |
Interest debt per share | 0.15 | 0.22 | 0.24 | 0.11 | 0.02 | |
Market cap | 350M | 350M | 137.72M | 42.54M | 28.14M | |
Enterprise value | 350.31M | 345.72M | 135.28M | 29.99M | 21.24M | |
P/E ratio | 65.64 | 69.12 | 43.68 | 39.51 | -3.62 | |
Price to sales ratio | 7.59 | 7 | 2.41 | 0.66 | 0.61 | |
POCF ratio | -603.24 | 68.95 | 399.15 | 3.36 | 90.14 | |
PFCF ratio | -292.34 | 75.8 | -43.74 | 4.53 | -8.27 | |
P/B Ratio | 17.59 | 13.41 | 2.51 | 0.8 | 0.66 | |
PTB ratio | 17.59 | 13.41 | 2.51 | 0.8 | 0.66 | |
EV to sales | 7.6 | 6.91 | 2.37 | 0.46 | 0.46 | |
Enterprise value over EBITDA | 41.93 | 47.91 | 32.04 | 6.55 | -14.48 | |
EV to operating cash flow | -603.78 | 68.11 | 392.08 | 2.37 | 68.05 | |
EV to free cash flow | -292.6 | 74.87 | -42.97 | 3.19 | -6.24 | |
Earnings yield | 0.02 | 0.01 | 0.02 | 0.03 | -0.28 | |
Free cash flow yield | 0 | 0.01 | -0.02 | 0.22 | -0.12 | |
Debt to equity | 0.25 | 0.29 | 0.15 | 0.03 | 0.01 | |
Debt to assets | 0.14 | 0.16 | 0.11 | 0.03 | 0.01 | |
Net debt to EBITDA | 0.04 | -0.59 | -0.58 | -2.74 | 4.7 | |
Current ratio | 2.14 | 2.04 | 2.22 | 3.27 | 5.18 | |
Interest coverage | 27.63 | 19.81 | 41.41 | 1.62 | 0 | |
Income quality | -0.1 | 1.03 | 0.11 | 9.26 | -0.04 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0.06 | |
Payout ratio | 0 | 0 | 0 | 0 | -0.23 | |
Sales general and administrative to revenue | 0 | 0.05 | 0.05 | 0.06 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0.02 | 0.01 | |
Intangibles to total assets | 0.05 | 0.04 | 0.03 | 0.03 | 0.07 | |
Capex to operating cash flow | 1.06 | -0.09 | -10.12 | -0.26 | -11.9 | |
Capex to revenue | -0.01 | -0.01 | -0.06 | -0.05 | -0.08 | |
Capex to depreciation | -0.52 | -0.39 | -2.76 | -2.61 | -3.25 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | -0.08 | |
Graham number | 1.4 | 1.56 | 1.83 | 1 | 2.42 | |
ROIC | 0.21 | 0.12 | 0.04 | 0.05 | -0.06 | |
Return on tangible assets | 0.16 | 0.11 | 0.04 | 0.02 | -0.16 | |
Graham Net | 0.09 | 0.23 | 0.24 | 0.36 | 0.65 | |
Working capital | 13.31M | 19.09M | 22.19M | 20.85M | 27.85M | |
Tangible asset value | 20.8M | 26.96M | 54.74M | 53.24M | 41.15M | |
Net current asset value | 12.34M | 18.22M | 21.68M | 20.47M | 27.83M | |
Invested capital | 0.25 | 0.29 | 0.15 | 0.03 | 0.01 | |
Average receivables | 5.69M | 9.58M | 13.04M | 9.16M | 5.61M | |
Average payables | 3.67M | 3.97M | 5.51M | 5.97M | 4.44M | |
Average inventory | 11.05M | 12.26M | 12.25M | 10.69M | 7.29M | |
Days sales outstanding | 51.8 | 92.04 | 86.01 | 27.42 | 49.91 | |
Days payables outstanding | 35.78 | 37.6 | 47.12 | 32.93 | 28.59 | |
Days of inventory on hand | 125.52 | 103.03 | 88.63 | 55.28 | 45.36 | |
Receivables turnover | 7.05 | 3.97 | 4.24 | 13.31 | 7.31 | |
Payables turnover | 10.2 | 9.71 | 7.75 | 11.08 | 12.77 | |
Inventory turnover | 2.91 | 3.54 | 4.12 | 6.6 | 8.05 | |
ROE | 0.27 | 0.19 | 0.06 | 0.02 | -0.18 | |
Capex per share | -0.02 | -0.01 | -0.1 | -0.09 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q4
Metric | History | 2022-03-31 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.92 | 0.41 | 0.82 | 0.48 | |
Net income per share | 0 | 0.03 | 0.01 | 0.01 | -0.23 | |
Operating cash flow per share | 0 | 0.24 | -0.01 | -0.01 | 0.02 | |
Free cash flow per share | 0 | 0.24 | -0.01 | -0.08 | -0.02 | |
Cash per share | 0 | 0.4 | 0.25 | 0.25 | 0.63 | |
Book value per share | 0 | 1.48 | 1.48 | 1.48 | 1.2 | |
Tangible book value per share | 0 | 1.49 | 1.43 | 1.43 | 1.15 | |
Share holders equity per share | 0 | 1.48 | 1.48 | 1.48 | 1.2 | |
Interest debt per share | 0 | 0.05 | 0 | 0.02 | 0.02 | |
Market cap | 0 | 42.54M | 26.42M | 46.3M | 28.14M | |
Enterprise value | 1.24M | 29.99M | 17.54M | 38.09M | 21.24M | |
P/E ratio | 0 | 10.76 | 26.66 | 23.36 | -0.85 | |
Price to sales ratio | 0 | 1.3 | 1.81 | 1.59 | 1.63 | |
POCF ratio | 0 | 5.02 | -117.67 | -103.11 | 36.97 | |
PFCF ratio | 0 | 4.92 | -66.1 | -17.24 | -39.27 | |
P/B Ratio | 0 | 0.8 | 0.5 | 0.88 | 0.66 | |
PTB ratio | 0 | 0.8 | 0.5 | 0.88 | 0.66 | |
EV to sales | 0 | 0.92 | 1.2 | 1.31 | 1.23 | |
Enterprise value over EBITDA | 0 | 18.99 | 84.3 | 88.57 | -11.2 | |
EV to operating cash flow | 0 | 3.54 | -78.12 | -84.83 | 27.91 | |
EV to free cash flow | 0 | 3.47 | -43.88 | -14.18 | -29.64 | |
Earnings yield | 0 | 0.02 | 0.01 | 0.01 | -0.29 | |
Free cash flow yield | 0 | 0.2 | -0.02 | -0.06 | -0.03 | |
Debt to equity | 0.23 | 0.03 | 0 | 0.01 | 0.01 | |
Debt to assets | 0.16 | 0.03 | 0 | 0.01 | 0.01 | |
Net debt to EBITDA | 0 | -7.95 | -42.68 | -19.09 | 3.64 | |
Current ratio | 1.94 | 3.27 | 2.95 | 2.95 | 5.18 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 8.56 | -0.91 | -0.91 | -0.09 | |
Dividend Yield | 0 | 0 | 0.03 | 0.04 | 0 | |
Payout ratio | 0 | 0 | 3.61 | 3.61 | 0 | |
Sales general and administrative to revenue | 0 | 0.05 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0.02 | 0 | 0 | 0.03 | |
Intangibles to total assets | 0.02 | 0.03 | 0.06 | 0.06 | 0.07 | |
Capex to operating cash flow | 0 | 0.02 | 0.78 | 4.98 | -1.94 | |
Capex to revenue | 0 | 0.01 | -0.01 | -0.08 | -0.09 | |
Capex to depreciation | 0 | 0.25 | -1.6 | -10.19 | -1.6 | |
Stock based compensation to revenue | 0 | 0 | 0 | -0.2 | 0.11 | |
Graham number | 0 | 0.96 | 0.48 | 0.68 | 2.5 | |
ROIC | 0 | 0.01 | 0 | 0 | -0.06 | |
Return on tangible assets | 0 | 0.02 | 0 | 0.01 | -0.17 | |
Graham Net | 0 | 0.36 | 0.25 | 0.25 | 0.65 | |
Working capital | 20.76M | 20.85M | 17.9M | 17.9M | 27.85M | |
Tangible asset value | 55.61M | 53.24M | 51.06M | 51.06M | 41.15M | |
Net current asset value | 20.3M | 20.47M | 17.58M | 17.58M | 27.83M | |
Invested capital | 0.23 | 0.03 | 0 | 0.01 | 0.01 | |
Average receivables | 0 | 0 | 5.12M | 5.38M | 0 | |
Average payables | 0 | 0 | 4.84M | 4.39M | 0 | |
Average inventory | 0 | 0 | 9.89M | 10.9M | 0 | |
Days sales outstanding | 0 | 13.38 | 33.18 | 16.59 | 33.04 | |
Days payables outstanding | 0 | 15.83 | 29.42 | 14.59 | 17.22 | |
Days of inventory on hand | 0 | 26.58 | 72.99 | 36.2 | 27.32 | |
Receivables turnover | 0 | 6.73 | 2.71 | 5.42 | 2.72 | |
Payables turnover | 0 | 5.68 | 3.06 | 6.17 | 5.23 | |
Inventory turnover | 0 | 3.39 | 1.23 | 2.49 | 3.29 | |
ROE | 0 | 0.02 | 0 | 0.01 | -0.19 | |
Capex per share | 0 | 0.01 | 0 | -0.06 | -0.04 |
QLI Frequently Asked Questions
What is Qilian International Holding Group Limited stock symbol ?
Qilian International Holding Group Limited is a CN stock and trading under the symbol QLI
What is Qilian International Holding Group Limited stock quote today ?
Qilian International Holding Group Limited stock price is $0.6438 today.
Is Qilian International Holding Group Limited stock public?
Yes, Qilian International Holding Group Limited is a publicly traded company.